Showing results (111-120 of 322) with videos related to
Sort By:
Pageof 33
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|May 22, 2020
[European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology]Eva Hadaschik, Rüdiger Eming, Lars E French, et al.Practical Neurology|July 21, 2022
Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guidelineMarija Cauchi, Mark Willis, Angela Andrews, et al.International Journal of Antimicrobial Agents|August 27, 2018
Exploring the relationship between primary care antibiotic prescribing for urinary tract infections, Escherichia coli bacteraemia incidence and antimicrobial resistance: an ecological studyHannah Lishman, Céire Costelloe, Susan Hopkins, et al.Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 26, 2021
Healthcare workers' knowledge, attitudes and behaviours with respect to antibiotics, antibiotic use and antibiotic resistance across 30 EU/EEA countries in 2019Diane Ashiru-Oredope, Susan Hopkins, Sagar Vasandani, et al.Immunotherapy|July 4, 2019
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continentsDaniel Suez, Gergely Kriván, Stephen Jolles, et al.Frontiers in Immunology|October 25, 2021
A Systematic Review and Meta-Analysis of Inpatient Mortality Associated With Nosocomial and Community COVID-19 Exposes the Vulnerability of Immunosuppressed AdultsMark J Ponsford, Tom J C Ward, Simon M Stoneham, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 19, 2017
Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der DermatologieAlexander Enk, Eva Hadaschik, Rüdiger Eming, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 31, 2016
European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatologyAlexander Enk, Eva Hadaschik, Rüdiger Eming, et al.Science Translational Medicine|November 3, 2017
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 studyPeter Kiessling, Rocio Lledo-Garcia, Shikiko Watanabe, et al.Journal of Clinical Immunology|November 25, 2025
CXCL13 as a Biomarker of Complex Common Variable ImmunodeficiencyIoasaf Karafotias, Helene Martini, Charlotte V Lee, et al.Pageof 33